Integrin alpha 4/CD49d Antibody (Natalizumab) [DyLight 550] - Chimeric
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75917R
Recombinant Monoclonal Antibody.
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Block/Neutralize, Flow Cytometry
Label
DyLight 550 (Excitation = 562 nm, Emission = 576 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # Natalizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary
Immunogen
The RAMOS cell line, a non-EBV releasing cell line, injected into mice.
Specificity
This antibody binds to the alpha 4 subunit of (alpha)4(beta)1 (also known as very late antigen 4 (VLA-4) or CD49d-CD29) and (alpha)4(beta)7 integrin
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Applications
Application
Recommended Usage
Block/Neutralize
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Integrin alpha 4/CD49d
Alternate Names
CD49d, ITGA4, VLA-4
Gene Symbol
ITGA4
Additional Integrin alpha 4/CD49d Products
Product Specific Notices
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...